The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAchieve Life Sciences has successfully completed the technology transfer for its smoking cessation drug candidate, cytisinicline, to Adare Pharma Solutions' facility in Ohio. This strategic move establishes domestic manufacturing capabilities within the United States and ensures supply chain redundancy. The company anticipates a commercial launch for the drug in the first half of 2027, contingent upon regulatory approval. Completing the transfer of analytical methods marks a significant operational milestone in the company's path toward commercialization. By partnering with a U.S.-based manufacturer, Achieve Life Sciences aims to mitigate logistical risks associated with global supply chains. This development underscores the company's commitment to building a robust production infrastructure ahead of its anticipated market entry.